Takeda plans growth in Russia with €75m Yaroslavl plant

Published: 11-Sep-2012

Will initially produce 90 million ampoules and more than 2 billion tablets a year


Takeda has completed a €75m pharmaceutical manufacturing facility in Russia, demonstrating its confidence in growth in the region.

The Japanese pharmaceutical manufacturer plans to boost sales of its products in Russia by 15% a year over the coming four years.

The 24,000m2 production plant, which is around 280km from Moscow, will employ 200 people and initially produce three Nycomed generic drugs, Cardiomagnyl, Actovegin and Calcium tablets for sale in Russia. Takeda purchased Nycomed for US$13.7bn last year.

The Yaroslavl plant will initially have the capacity to produce 90 million sterile ampoules and more than 2 billion tablets a year. It is expected to be fully operational by 2014.

Liquid sterile production includes solution preparation, washing of ampoules, sterilisation, filling, inspection, and packaging. Solid production will encompass all stages, from weighing, mixing and granulation through compression, coating, and packaging.

Yasuchika Hasegawa, president and chief executive of Takeda Pharmaceutical Company, said: ‘The completion of this ambitious project further demonstrates Takeda’s transition into a truly global business, and strategic investment into key emerging markets such as Russia is a major part of this strategy.’

‘Russia is our largest emerging market in terms of revenues, and is expected to contribute significantly to our growth over the next few years.’

IMS Health, the healthcare consultancy, estimated total pharmaceutical sales in Russia of $14.7bn last year, making it the 11th largest pharmaceutical market in the world. It forecast sales growth in the Commonwealth of Independent States region to grow at a compound annual rate of 11% between 2012 and 2016.

You may also like